111 related articles for article (PubMed ID: 2831047)
1. Comparative in vitro activity of the new peptolide antibiotic LY146032 against staphylococci.
Peters G; Schumacher-Perdreau F; Pulverer G
Eur J Clin Microbiol; 1987 Dec; 6(6):685. PubMed ID: 2831047
[No Abstract] [Full Text] [Related]
2. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
Hodinka RL; Jack-Wait K; Wannamaker N; Walden TP; Gilligan PH
Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.
Machka K; Braveny I
Eur J Clin Microbiol; 1987 Feb; 6(1):96-9. PubMed ID: 3032613
[TBL] [Abstract][Full Text] [Related]
4. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.
Benson CA; Beaudette F; Trenholm G
J Antimicrob Chemother; 1987 Aug; 20(2):191-6. PubMed ID: 2822645
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of LY146032 (daptomycin), a new peptolide.
Ehlert F; Neu HC
Eur J Clin Microbiol; 1987 Feb; 6(1):84-90. PubMed ID: 3032611
[TBL] [Abstract][Full Text] [Related]
6. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.
Pohlod DJ; Saravolatz LD; Somerville MM
J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Staphylococcus aureus and coagulase-negative staphylococci with decreased sensitivity to glycopeptides as assessed by determination of MICs.
Vedel G; Leruez M; Lémann F; Hraoui E; Ratovohery D
Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):820-2. PubMed ID: 2150815
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.
Jorgensen JH; Maher LA; Redding JS
Eur J Clin Microbiol; 1987 Feb; 6(1):91-6. PubMed ID: 3032612
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
Bartoloni A; Colao MG; Orsi A; Dei R; Giganti E; Parenti F
J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
[TBL] [Abstract][Full Text] [Related]
10. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.
Stratton CW; Liu C; Weeks LS
Antimicrob Agents Chemother; 1987 Aug; 31(8):1210-5. PubMed ID: 2820300
[TBL] [Abstract][Full Text] [Related]
11. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
Bezian MC; Ribou G; Masquelier B
Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
[TBL] [Abstract][Full Text] [Related]
12. Comparative activity of LY146032 against anaerobic cocci.
Greenwood D; Palfreyman J
Eur J Clin Microbiol; 1987 Dec; 6(6):682-4. PubMed ID: 2831046
[TBL] [Abstract][Full Text] [Related]
13. In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis.
Coudron PE; Johnston JL; Archer GL
J Antimicrob Chemother; 1987 Oct; 20(4):505-11. PubMed ID: 2824426
[TBL] [Abstract][Full Text] [Related]
14. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.
Lopez S; Hackbarth C; Romanò G; Trias J; Jabes D; Goldstein BP
J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii21-4. PubMed ID: 15750033
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of the new glycopeptide decaplanin.
Neu HC; Chin NX; Niu WW
Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):458-62. PubMed ID: 1330562
[TBL] [Abstract][Full Text] [Related]
16. Synergy study of vancomycin or teicoplanin plus gentamicin against enterococci, Staphylococcus aureus and coagulase-negative staphylococci by time-kill method.
Thamlikitkul V
J Med Assoc Thai; 1991 Dec; 74(12):669-74. PubMed ID: 1839906
[TBL] [Abstract][Full Text] [Related]
17. Antistaphylococcal activity of a cyclic peptide, LY146032, and vancomycin.
Knapp CC; Washington JA
Antimicrob Agents Chemother; 1986 Dec; 30(6):938-9. PubMed ID: 3028254
[TBL] [Abstract][Full Text] [Related]
18. Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus.
Flandrois JP; Fardel G; Carret G
Antimicrob Agents Chemother; 1988 Apr; 32(4):454-7. PubMed ID: 2837137
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activity of teicoplanin and vancomycin against United States teicoplanin clinical trial isolates of gram-positive cocci.
Kenny MT; Dulworth JK; Brackman MA
Diagn Microbiol Infect Dis; 1991; 14(1):29-31. PubMed ID: 1826479
[TBL] [Abstract][Full Text] [Related]
20. Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus.
Carper HT; Sullivan GW; Mandell GL
J Antimicrob Chemother; 1987 May; 19(5):659-62. PubMed ID: 2956229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
